SCHEMBL3419917

SCHEMBL3419917

Cc1cc(N2C[C@H](CNC(=O)c3ccc(Cl)s3)OC2=O)cc(C)c1-n1cccc(OCCN[C@H]2CC[C@H](O)CC2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.57
F2 P00734 4/20 0.57
THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3419919 1.00 F10 (0.57) F10F2THRB
SCHEMBL13251105 1.00 F10 (0.57) F10F2THRB
SCHEMBL3420989 0.92 F10 (0.68) F10F2THRB
SCHEMBL3420985 0.92 F10 (0.68) F10F2THRB
SCHEMBL2589222 0.90 F10 (0.67) F10F2
SCHEMBL2589221 0.90 F10 (0.67) F10F2
SCHEMBL3419937 0.90 F10 (0.64) F10F2THRB
SCHEMBL13251066 0.89 F10 (0.71) F10F2THRB
SCHEMBL3757444 0.89 F10 (0.67) F10F2THRB
SCHEMBL3421568 0.88 F10 (0.64) F10F2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
EP-2170877-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER IP GMBH (DE) 2012-11-21 EP disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
EP-2170877-A1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer HealthCare AG (DE) 2010-04-07 EP disclosed
WO-2008155032-A1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L F10 360/4885F2 30/4885THRB 3871/4885
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L F10 360/4885F2 30/4885THRB 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.